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Human papillomavirus type 58 (HPV-58) exists in a relatively high prevalence in certain parts of the world,
including East Asia. This study examined the T-cell response to HPV-58 L1, E6, and E7 peptides among women
with cleared infection, cervical intraepithelial neoplasia grade 2 (CIN2) or CIN3, or invasive cervical cancer
(ICC). Peptides found to be reactive in the in vitro peptide binding assay or mouse-stimulating study were
tested with a gamma interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay to detect peptide-
specific responses from the peripheral blood mononuclear cells (PBMC) collected from 91 HPV-58-infected
women (32 with cleared infection, 16 CIN2, 15 CIN3, and 28 ICC). Four HLA-A11-restricted HPV-58 L1
peptides, located at amino acid positions 296 to 304, 327 to 335, 101 to 109, and 469 to 477, showed positive
IFN- ELISPOT results and were mainly from women with cleared infection. Two HLA-A11-restricted E6
peptides (amino acid positions 64 to 72 and 94 to 102) and three HLA-A11-restricted E7 peptides (amino acid
positions 78 to 86, 74 to 82, and 88 to 96) showed a positive response. A response to E6 and E7 peptides was
mainly observed from subjects with CIN2 or above. One HLA-A2-restricted E6 peptide, located at amino acid
position 99 to 107, elicited a positive response in two CIN2 subjects. One HLA-A24-restricted L1 peptide,
located at amino acid position 468 to 476, also elicited a positive response in two CIN2 subjects. In summary,
this study has identified a few immunogenic epitopes for HPV-58 E6 and E7 proteins. It is worthwhile to further
investigate whether responses to these epitopes have a role in clearing an established cervical lesion.
Infection with high-risk human papillomaviruses (HPV) is a
necessary cause for cervical cancer (14, 21, 33). Of the more
than 40 HPV types that can infect the female genital tract, at
least 15 have been shown to be associated with an increased
risk for cancer development (21), and HPV type 16 (HPV-16)
and HPV-18 account for more than 70% of cervical cancers
detected worldwide (6, 10, 28). Currently, two vaccines have
been approved for clinical use to prevent HPV infection and its
potential consequences of developing cervical intraepithelial
neoplasia (CIN) and invasive cervical cancer (ICC) (27). Both
vaccines are prophylactic and contain HPV-16 and HPV-18 L1
protein-based virus-like particles. To date, the development of
therapeutic vaccines has been restricted to early-phase clinical
trials, and none has been approved for clinical use. HPV-
specific cytotoxic cellular immunity against the E6 and E7
proteins that are consistently expressed in cervical neoplasia is
important in clearing the established lesions. The results of
initial studies using in vitro and in vivo models demonstrated
that viral peptides were able to stimulate murine cytotoxic
T-lymphocytes, and these peptides were also able to stimulate
human cytotoxic T-lymphocytes against HPV-positive cervical
cell lines (1, 13, 25). These findings have led to the search for
peptides that can elicit or augment an HPV-specific cytotoxic
cellular response from patients who have developed preinva-
sive or invasive cervical neoplasia (4, 29, 35). While HPV-16
and HPV-18 are the most prevalent HPV types found in cer-
vical cancers detected worldwide, HPV-58 has been found at a
relatively higher frequency in East Asia (5, 7). Currently, data
on T-cell response to HPV-58 peptides are not available;
therefore, the aim of this study was to characterize the T-cell
response against peptides derived from the L1, E6, and E7
proteins of HPV-58 among women with cleared infection or
cervical neoplasia.
MATERIALS AND METHODS
HLA-11 peptide selection by in vitro peptide binding assay. The HLA-A*1101
(HLA-A11) heavy (H) chain and B2M were refolded in the presence of the
synthetic peptides (Table 1). The resultant complexes were then analyzed by a
sandwich enzyme-linked immunosorbent assay (ELISA). Briefly, the HLA-A11
H chain and B2M were mixed with each candidate peptide at a molecular ratio
of 1:1:3. After incubation at 4°C for 24 to 48 h, the soluble portion was concen-
trated using a Centricon centrifugal filter unit (YM100; Millipore, Billerica,
MA), followed by ELISA analysis.
An in vitro ELISA-based peptide-binding assay was conducted based on a
protocol reported previously, with minor modifications (9). Briefly, a 96-well
microtiter plate coated with 5 g/ml of anti-HLA antibody (W6/32) in 100 mM
carbonate buffer (pH 9.6) was incubated at 4°C overnight. After blocking with
10% nonfat milk in phosphate-buffered saline (PBS), the concentrated refolded
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complexes were added, and horseradish peroxidase (HRP)-conjugated rabbit
anti-human B2M (1:2,500) was used to detect complex formation. The enhancing
reagent EnVision-HRP (Dako, Denmark) was used to amplify the signal. The
substrate 3,3,5,5-tetramethylbenzidine (TMB) was used for color development,
which was stopped with 1 N sulfuric acid. Optical density was measured at 450
nm using a plate reader (Molecular Devices, Sunnyvale, CA).
HLA-A2 and -A24 peptide selection by immunization of HLA-A2 or HLA-A24
transgenic mice. One-milligram amounts of the indicated nonamers (Tables
2 and 3) and 1 mg of PADRE peptide (AKFVAAWTLKAAA) in 0.5 ml PBS
were mixed well with 0.5 ml incomplete Freund’s adjuvant (IFA). The positive-
control peptides for HLA-A2 and HLA-A24 were from HPV-16 E7 and Epstein-
Barr virus (EBV) LMP-2, respectively. One hundred microliters of each mixture
was subcutaneously injected into the tail base of HLA-A2- or HLA-24-transgenic
mice twice at a 7-day interval. Spleen cells were harvested 7 days after the second
injection and cultured with 10 g/ml of peptides for 48 h, followed by a gamma
interferon (IFN-) enzyme-linked immunospot (ELISPOT) assay (eBioscience,
San Diego, CA). The wells of 96-well plates with nitrocellulose membrane inserts
were coated with 50 l of anti-IFN- antibody solution (clone AN18, 10 g/ml in
1 PBS; eBioscience) and incubated for 18 h at 4°C. The plates were then
washed with PBS four times and blocked with 100 l of RPMI medium supple-
mented with 10% fetal bovine serum (FBS) (RPMI-10) per well for 1 to 3 h to
prevent nonspecific binding in later steps. Next, 2  105 or 5  105 splenocytes
with 10 g/ml of the indicated peptides were added to the plate at a final volume
of 200 l of RPMI-10 (Tables 2 and 3). The ELISPOT assay was performed in
triplicate for each experimental condition. Specifically, the plates were incubated
in a humidified atmosphere of 5% CO2 in air at 37°C for 48 h. After this
incubation, the cells were removed from the plate by washing six times with
0.05% (wt/vol) Tween 20 in PBS. A 50-l aliquot of biotinylated anti-IFN-
antibody (clone R46A2, 2 g/ml in PBS; eBioscience) was then added to each
well. The plates were again incubated in a humidified atmosphere of 5% carbon
dioxide in air at 37°C for 2 h. The washing steps were repeated. After an hour of
incubation with an avidin-HRP complex reagent (eBioscience) at room temper-
ature, the plates were washed again three times with 0.05% (wt/vol) Tween 20 in
PBS and then three times with PBS alone. A 100-l aliquot of 3-amine-9-ethyl
carbazole (ACE; Sigma-Aldrich, St. Louis, MO) staining solution was added to
each well to develop the spots. The reaction was stopped after 4 to 6 min by
placing the plate under tap water. The spots were then counted using an
ELISPOT reader (Cellular Technology Ltd., Shaker Heights, OH).
Study subjects. Women with abnormal cytology results were recruited from
the colposcopy clinic of Prince of Wales Hospital in Hong Kong from 2006 to
TABLE 1. Results of in vitro peptide binding assay for HLA-A11-
restricted cytotoxic-T-lymphocyte epitopes derived
from HPV-58 E6, E7, and L1 proteins
Protein Peptide sequence Amino acidposition
Relative binding
ability (%)
HPV-58 L1 SIKSPNNNK 77–85 249.9
RVRLPDPNK 101–109 387.3
AVPDDLYIK 296–304 406.2
TSESQLFNK 327–335 126.9
MTLCTEVTK 368–376 332.3
EVTKEGTYK 373–381 23.2
GTYKNDNFK 378–386 321.6
LQFVFQLCK 397–405 255.7
YTFWEVNLK 469–477 181.9
LLQSGLKAK 494–502 7.0
PTTRAPSTK 510–518 48.6
RAPSTKRKK 513–521 9.8
STKRKKVKK 516–524 145.6
HPV-58 E6 QALETSVHE 17–25 0
TSVHEIELK 21–29 58.7
KVCLRLLSK 64–72 142.2
SLYGDTLEQ 82–90 0
DTLEQTLKK 86–94 7.6
KCLNEILIR 94–102 56.4
RPLCPQEKK 108–116 3.2
HPV-58 E7 CYTCGTTVR 59–67 10.4
LCINSTATE 68–76 0
ATEVRTLQQ 74–82 0
CTIVCPSCA 88–96 0.8
TIVCPSCAQ 89–97 3.3
EBV EBNA3B
(positive control)
IVTDFSVIK 416–424 100
TABLE 2. Results of mouse immunization study for HLA-A24-
restricted cytotoxic-T-lymphocyte epitopes derived from
HPV-58 L1 and E6 proteins
Protein Peptide sequence Amino acidposition
No. of IFN-
spots/1  106
cellsa
HPV-58 E6 VYDFVFADL 42–50 155
DFVFADLRI 44–52 0
VFADLRIVY 46–54 48
VYRDGNPFA 53–61 0
PFAVCKVCL 59–67 0
VCLRLLSKI 65–73 0
EYRHYNYSL 75–83 0
HPV-58 L1 EYVSRTSIY 52–60 0
YYYAGSSRL 60–68 0
YYAGSSRLL 61–69 0
QYRVFRVRL 96–104 0
VRLPDPNKF 102–110 0
FYNPDTQRL 117–125 0
DYKQTQLCL 117–185 0
FFPTPSGSI 317–325 348
EYVRHVEEY 387–395 0
VFQLCKITL 400–408 15
TYIHTMDSN 414–422 7
TYRFVTSQA 442–450 39
KYTFWEVNL 468–476 103
KFSADLDQF 479–487 0
EBV LMP-2 TYGPVFMCL 419–427 101
a The data represent the average numbers of spots from three mice.
TABLE 3. Results of mouse immunization study for HLA-A2-
restricted cytotoxic-T-lymphocyte epitopes derived from
HPV-58 E6 and E7 proteins
Protein Peptide sequence Amino acidposition
No. of IFN-
spots/1  106
cellsa
HPV-58 E6 TLHDLCQAL 11–19 0
ALETSVHEI 18–26 64
FVFADLRIV 45–53 0
AVCKVCLRL 61–69 0
VCLRLLSKI 65–73 37
RLLSKISEY 68–76 0
TLEQTLKKC 87–95 0
TLKKCLNEI 91–99 0
ILIRCIICQ 99–107 17
HPV-58 E7 TLREYILDL 7–15 0
DLHPEPTDL 14–22 0
CINSTATEV 69–77 13
STATEVRTL 72–80 0
EVRTLQQLL 76–84 0
TLQQLLMGT 79–87 0
QLLMGTCTI 82–90 0
HPV-16 E7 YMLDLQPETT 11–20 25
a The data represent the average numbers of spots from three mice.
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2008. In addition, patients with ICC were also recruited from the oncology clinic
of the same hospital. The remainders of cervical scrape samples submitted for
routine cytological examination were used for HPV detection and typing. Briefly,
HPV DNA was detected by a single-round PCR based on the PGMY09/11
primer set according to a method described previously (8). To identify HPV-58-
positive subjects, samples positive for HPV DNA were either typed by restriction
fragment length polymorphisms or by using a linear array HPV genotyping kit
(Roche Molecular Diagnostics, CA), as described previously (5, 8).
The cervical disease status was confirmed by histology. Patients who had no
abnormalities detected by colposcopy and, hence, did not have biopsy specimens
taken were followed up by cytology every 6 months. A cleared, self-limiting
HPV-58 infection was defined as having had HPV-58 detected in the first visit
and becoming negative for at least two subsequent follow-up visits, with the
cytology results returned to normal.
Subjects who were found to be positive for HPV-58 and with a cervical disease
status confirmed by histology or with a cleared infection were invited to donate
blood for HLA typing and T-cell epitope mapping. The HLA class 1A alleles of
the study subjects were identified using the AccuPlex typing kit (Dynal Biotech,
Wirral, United Kingdom). This kit provides low-resolution typing. Briefly, pe-
ripheral blood mononuclear cells (PBMC) were used as a source of genomic
DNA for PCR amplification using locus-specific primers. The biotinylated PCR
products were hybridized to sequence-specific oligonucleotide probes, with the
final signals recorded by a Luminex flow analyzer. AccuMatch software was used
for HLA assignment. Subjects who belonged to the three most common HLA
types (A11, A24, or A2) were selected for T-cell epitope study.
All study subjects provided informed consent. The study was approved by the
local institutional ethics committee.
Isolation of PBMC. PBMC were isolated by Ficoll-Paque Plus gradient cen-
trifugation (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Recovered
PBMC were washed, assessed for viability by trypan blue exclusion, and cryo-
preserved at 1  107 cells/ml in freezing medium containing 10% dimethyl
sulfoxide (Sigma, St. Louis, MO) and 90% FBS (HyClone, MA).
Peptide stimulation of PBMC. Peptides showing positive results from the in
vitro binding assay or mouse immunization study were selected for IFN-
ELISPOT assay (Table 4).
Cryopreserved PBMC were thawed and washed twice with AIM-V-RPMI 1640
containing 2 mM glutamine, 25 mM HEPES (Invitrogen, Carlsbad, CA) supple-
mented with 50 M 2-mercaptoethanol (Sigma, St. Louis, MO), 0.1 M nones-
sential amino acid solution (Invitrogen, Carlsbad, CA), and 10% human AB
serum (Sigma, St. Louis, MO). The viable cells were counted using trypan blue
exclusion and resuspended at 3  105 cells/ml. One milliliter of the PBMC
suspension was added to a 24-well plate (Costar; Corning Incorporated, NY)
before the addition of the HLA-matched peptides, each at a concentration of 10
g/ml. For the positive control, PBMC were cultured with an HLA-A2-, -A11-,
or -A24-restricted positive peptide pool containing peptides from EBV and
human cytomegalovirus (CMV) at 10 g/ml each (Table 5). The PBMC were
prestimulated for a total of 4 days at 37°C. On day 3, 1 ml of AIM-V-RPMI 1640
medium containing 20 IU/ml recombinant interleukin-2 (AbD Serotec, Oxford,
United Kingdom) was added. On the next day (day 4), 1 ml of culture medium
was removed and replaced with 1 ml of fresh AIM-V-RPMI 1640, and the culture
was further incubated at 37°C for 18 to 20 h.
IFN- ELISPOT assay. On day 5, peptide-pulsed PBMC were harvested and
washed once, and the viable cells counted using trypan blue exclusion. The cell
concentration was adjusted to give 2  105 cells/ml. The wells of a multiscreen
96-well plate (Millipore, Billerica, MA) that was prewetted with 35% alcohol
were washed three times with PBS (Invitrogen, Carlsbad, CA), coated with 100
l of IFN- capture antibody (R&D Systems, Minneapolis, MN), and left over-
night at 4°C. On the next day, before use, the plate wells were washed four times
with PBS and blocked at room temperature with 200 l of AIM-V-RPMI 1640
medium containing 10% FBS for at least 2 h before PBMC seeding. PBMC that
had been prestimulated with the appropriate peptides were seeded in triplicates
at 104 cells per well. A total of 104 autologous PBMC that acted as antigen-
presenting cells (APCs) were also added to each test well. The total volume of
medium per well was 100 l. Fresh peptides, each at a concentration of 10 g/ml,
were added to each well. For the positive controls, PBMC that had been pulsed
with the HLA-A2-, -A11-, or -A24-restricted positive peptide pool were cultured
again with a fresh positive peptide pool at 10 g/ml each (Table 5). PBMC
stimulated with concanavalin A (Calbiochem, United States) at a concentration
of 0.5 g/ml were used as a positive control for lymphocyte activation. Negative-
control wells contained only PBMC that had gone through 4 days of incubation
in the absence of peptide. For background controls, only APCs were incubated.
The 96-well ELISPOT plate was wrapped in aluminum foil to maintain well-to-
well reproducibility and to minimize background staining and was incubated at
37°C for a further 18 to 20 h. The ELISPOT plate was washed four times with
0.05% Tween 20–PBS, and then 100 l of human IFN- detection antibody was
added (R&D Systems, Inc., Minneapolis, MN) and incubated at 4°C for 12 to
16 h. After this, the washings were repeated and 100 l of streptavidin-alkaline
phosphatase (R&D Systems, Inc., Minneapolis, MN) in 10% FBS diluted with
TABLE 4. HPV-58 peptides used in IFN- ELISPOT study for
subjects with cleared infection or cervical neoplasia
Peptide sequence
HLA
restriction
type
Gene region, amino
acid position in
HPV-58a
% Similarityb to
corresponding peptide
in HPV-16/-18
SIKSPNNNK A11 L1, 77–85 HPV-16, L1 77–85,
78
RVRLPDPNK A11 L1, 101–109 —
AVPDDLYIK A11 L1, 296–304 HPV-16, L1 296–
304, 89
TSESQLFNK A11 L1, 327–335 HPV-18, L1 362–
370, 89
MTLCTEVTK A11 L1, 368–376 —
GTYKNDNFK A11 L1, 378–386 —
LQFVFQLCK A11 L1, 397–405 —
YTFWEVNLK A11 L1, 469–477 HPV-16, L1 470–
478, 100
STKRKKVKK A11 L1, 516–524 —
TSVHEIELK A11 E6, 21–29 —
KVCLRLLSK A11 E6, 64–72 —
KCLNEILIR A11 E6, 94–102 —
CYTCGTTVR A11 E7, 59–67 —
ATEVRTLQQ A11 E7, 74–82 —
LCINSTATE A11 E7, 68–76 —
CTIVCPSCA A11 E7, 88–96 —
TIVCPSCAQ A11 E7, 89–97 —
VYDFVFADL A24 E6, 42–50 —
VFADLRIVY A24 E6, 46–54 —
FFPTPSGSI A24 L1, 317–325 HPV-16, L1 317–
325, 78
VFQLCKITL A24 L1, 400–408 —
TYIHTMDSN A24 L1, 414–422 HPV-16, L1 415–
423, 67
TYRFVTSQA A24 L1, 442–450 HPV-16, L1 443–
451, 100
KYTFWEVNL A24 L1, 468–476 HPV-16, L1 469–
477, 100
ALETSVHEI A2 E6, 18–26 —
VCLRLLSKI A2 E6, 65–73 —
ILIRCIICQ A2 E6, 99–107 —
CINSTATEV A2 E7, 69–77 —
a Amino acid position numbering is according to the HPV-58 prototype
(GenBank accession no. D90400).
b —, similarity was 60%.
TABLE 5. Positive peptide pool used in IFN- ELISPOT study for
subjects with cleared infection or cervical neoplasia
HLA restriction
type Peptide sequence
Amino acid
position Virus,
a protein
A2 VLGPISGHV 14–22 CMV, pp65
A2 MLNIPSINV 120–128 CMV, pp65
A2 NLVPMVATV 495–503 CMV, pp65
A2 RIFAELEGV 522–530 CMV, pp65
A11 AVFDRKSDAK 399–408 EBV, EBNA3B
A11 GPISGHVLK 16–24 CMV, pp65
A11 ATVQGQNLK 501–509 CMV, pp65
A24 RYSIFFDY 246–253 EBV, EBNA3A
A24 TYGPVFMCL 419–427 EBV, LMP2
A24 VYALPLKML 113–121 CMV, pp65
a EBV, Epstein-Barr virus; CMV, cytomegalovirus.
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PBS was added to each well. This was further incubated at room temperature for
2 h. The plate was washed again with 0.05% Tween 20–PBS, and 100 l of
5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium (BCIP-NBT) chro-
mogen (R&D Systems, Inc., Minneapolis, MN) was added and incubated for 30
min for color development. The reaction was stopped by washing six times with
distilled water. The spots were counted using a cytotoxic-T-lymphocyte Immu-
noSpot S4 UV analyzer (C.T.L. Cellular Technology Ltd., United States).
Criteria used in previously published studies were adopted to assign a specific
response (29, 32). The net spot count for each peptide was obtained by subtract-
ing the average results for background controls that contain only APCs from the
total number of spots observed in the test well. For a significant T-cell response,
the mean net spot count in the peptide test wells must have been greater than the
mean plus twice the standard deviation of those of the negative-control wells and
at the same time greater than 10 spots.
RESULTS
Peptide selection. Altogether, nine HLA-A11-restricted L1
peptides and three A11-restricted E6 peptides showed a rela-
tive binding ability greater than 50% of that of the positive
control (Table 1). In the mouse immunization study, five A24-
restricted L1 peptides, two A24-restricted E6 peptides, three
A2-restricted E6 peptides, and one A2-restricted E7 peptide
showed positive results (Tables 2 and 3). These peptides were
selected for further IFN- ELISPOT study using human
PBMC samples. In addition, five A11-restricted E7 peptides
with high scores from bioinformatic prediction were also in-
cluded (Table 4). Of these peptides selected for further study,
three L1 peptides showed 100% similarity with HPV-16 L1
(Table 4).
Subject distribution. A total of 91 subjects were recruited
for the T-cell response study using the IFN- ELISPOT assay.
Thirty-two patients aged 36 to 56 (mean, 45.3; standard devi-
ation [SD], 10.3) years had cleared HPV-58 infection, with
cytology returning to normal, and had become HPV negative
on follow-up. Thirty-one patients aged 32 to 75 (mean, 43.6;
SD, 11.6) years had histology-confirmed CIN (16 CIN2 and 15
CIN3). Twenty-eight patients aged 31 to 77 (mean, 59.5; SD,
12.4) years had ICC (27 squamous cell carcinoma and 1 un-
differentiated carcinoma).
HPV-58 infection. All 91 study subjects had HPV-58 DNA
detected from their cytology specimens. Altogether, 73 sub-
jects had HPV-58 as a single infection (25 cleared infections,
12 CIN2, 12 CIN3, and 24 ICC), and 18 subjects had HPV-58
detected together with one or more other HPV types (7
cleared infections, 4 CIN2, 3 CIN3, and 4 ICC). The propor-
tions of single versus coinfections among women with different
cervical states were not significantly different (P value of 0.826
by Chi-squared test).
HLA-A11-specific T-cell epitopes identified from human
PBMC. Altogether, 53 subjects (17 cleared infections, 10
CIN2, 10 CIN3, and 16 ICC) either homozygous or heterozy-
gous for HLA-A11 were studied. The results showed four L1
peptides with a positive response in the IFN- ELISPOT assay.
These four peptides were located at amino acid positions 101
to 109, 296 to 304, 327 to 335, and 469 to 477 of the HPV-58
L1 protein (L1 101–109, 296–304, 327–335, and 469–477 pep-
tides) (Table 4). The mean net number of IFN- spots de-
tected ranged from 12 to 54 per 104 cells. All peptides, except
L1 296–304, only had positive signals detected from the PBMC
collected from patients with cleared infection. The positive
rate among subjects with cleared infection was 41.2% for pep-
tide L1 101–109, 11.8% for L1 296–304, 35.3% for L1 327–335,
and 47.1% for L1 469–477.
Two E6 peptides, located at amino acid positions 64 to 72
and 94 to 102, were found to elicit positive responses for
HLA-A11 subjects. One (5.9%) subject with cleared infection,
two (20.0%) CIN2 subjects, and four (25.0%) ICC subjects had
positive responses to the E6 64–72 peptide. Although a higher
response rate was found among CIN2 and ICC subjects, the
difference was not statistically significant. The E6 94–102 pep-
tide showed positive responses only in two of the 10 CIN2
subjects and in none of the subjects with cleared infection,
CIN3, or ICC (Table 6).
Three peptides located at amino acid positions 74 to 82, 78
to 86, and 88 to 96 of the HPV-58 E7 protein elicited positive
responses in the IFN- ELISPOT assay. The E7 78-86 peptide
showed positive responses from two (20.0%) CIN2 subjects,
and the E7 88-96 peptide showed positive responses from two
(12.5%) ICC subjects, while the E7 74-82 peptide showed
positive responses across all grades of cervical lesions, includ-
ing three (17.6%) cleared infections, four (40.0%) CIN2, two
(20.0%) CIN3, and three (18.8%) ICC (Table 6).
Of the 10 HLA-A11 subjects with coinfections, four had
positive responses (two subjects with cleared infection re-
sponded to L1 101-109, 327-335, and 469-477; another subject
with cleared infection responded to L1 327-335; and a subject
with CIN2 responded to L1 296-304). The positive response
rates among groups with single and coinfections were not sig-
nificantly different (19.0% versus 27.3%, P value of 0.615 by
Chi-squared test).
Overall, the positive subjects responded to 1 to 4 (median,
2) peptides. Among the 13 subjects with cleared infection
who showed positive response, five (38.5%) responded to
one peptide, three (23.1%) responded to two peptides, four
(30.8%) responded to three peptides, and another (7.6%) re-
sponded to four peptides. For those with CIN2, two subjects
responded to one peptide, one responded to two peptides, two
responded to three peptides, and another responded to four
peptides. The two subjects with CIN3 responded to only one
peptide, while one subject with ICC responded to one peptide,
one responded to two, and the other two responded to three
peptides.
HLA-A2-specific T-cell epitopes identified from human
PBMC. Forty-eight subjects (15 cleared infections, 12 CIN2, 5
CIN3, and 16 ICC) either homologous or heterozygous for the
HLA-A2 allele were tested for HPV-58 E6 and E7 peptides.
One E6 peptide located at amino acid position 99 to 107
elicited positive responses from two (16.7%) CIN2 subjects
with HPV-58 single infection.
HLA-A24-specific T-cell epitopes identified from human
PBMC. Thirty-nine subjects (14 cleared infections, 4 CIN2, 9
CIN3, and 12 ICC) either homologous or heterozygous for the
HLA-A24 allele were studied. As a result, one L1 peptide
located at amino acid position 468 to 476 was found to have a
positive response in two (50.0%) CIN2 subjects who had an
HPV-58 single infection (Table 2).
DISCUSSION
The strong association between HPV infection and the de-
velopment of cervical cancer provides an opportunity to tackle
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cervical cancer by controlling HPV infection (20, 37). The
success of prophylactic vaccines has provided a strong impetus
to further work in this direction (15, 16, 17, 24). The foreign
viral proteins E6 and E7 that are constitutively expressed in
tumor cells serve as potential targets for immune clearance
and, thus, are the prime targets for therapeutic vaccine devel-
opment (2, 19, 29, 35). However, it is well documented that
lesions that have progressed to a late precancerous or invasive
stage often exhibit features of immune escape. The identifica-
tion of viral epitopes that remain visible to the immune sur-
veillance of women with precancers and invasive cancers is
therefore an important step leading to the development of a
successful therapeutic vaccine.
Previous studies have mainly focused on HPV-16 and, to a
TABLE 6. IFN- ELISPOT results according to HLA type and cervical status
HLA
Encoding
region, amino
acid positiona
Cervical status
No. with positive
ELISPOT result/
no. tested (%)b
Mean IFN- spot-
forming count
(range, SD)/104 cells
P valuec
A11 L1, 101–109 Cleared infection 7/17 (41.2) 31.7 (18–43, 9.4) 0.001
CIN2 0/10 (0)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 L1, 296–304 Cleared infection 2/17 (11.8) 32.5 (29–36, 4.9) 1.0
CIN2 4/10 (40.0) 16.3 (12–21, 4.0)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 L1, 327–335 Cleared infection 6/17 (35.3) 35.5 (26–54, 10.4) 0.001
CIN2 0/10 (0)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 L1, 469–477 Cleared infection 8/17 (47.1) 33.0 (16–45, 10.2) 0.001
CIN2 0/10 (0)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 E6, 64–72 Cleared infection 1/17 (5.9) 15.0 0.408
CIN2 2/10 (20.0) 16.0 (15–17, 1.4)
CIN3 0/10 (0)
ICC 4/16 (25.0) 19.3 (14–25, 4.8)
A11 E6, 94–102 Cleared infection 0/17 (0) 1.0
CIN2 2/10 (20.0) 14.7 (11–18, 3.5)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 E7, 74–82 Cleared infection 3/17 (17.6) 24.0 (18–30, 6.1) 0.730
CIN2 4/10 (40.0) 19.8 (12–28, 7.5)
CIN3 2/10 (20.0) 14.0 (12–16, 2.8)
ICC 3/16 (18.8) 16.0 (13–20, 3.6)
A11 E7, 78–86 Cleared infection 0/17 (0) 1.0
CIN2 2/10 (20.0) 13.0 (12–14, 1.4)
CIN3 0/10 (0)
ICC 0/16 (0)
A11 E7, 88–96 Cleared infection 0/17 (0) 1.0
CIN2 0/10 (0)
CIN3 0/10 (0)
ICC 2/16 (12.5) 13.0 (15–20, 3.5)
A2 E6, 99–107 Cleared infection 0/15 (0) 1.0
CIN2 2/12 (16.7) 14.0 (11–17, 4.2)
CIN3 0/5 (0)
ICC 0/16 (0)
A24 L1, 468–476 Cleared infection 0/14 (0) 1.0
CIN2 2/4 (50.0) 15.0 (12–18, 4.3)
CIN3 0/9 (0)
ICC 0/12 (0)
a Amino acid position numbering is according to the HPV-58 prototype (GenBank accession no. D90400).
b Subjects with heterozygous HLA-A alleles were tested for each of the HLA types and, therefore, counted twice.
c Positive response rate among subjects with cleared infection compared to that in subjects with CIN2/CIN3/ICC by 2-tailed Fisher’s exact test.
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small extent, HPV-18, the most common HPV types found in
cervical cancers worldwide. Earlier studies have shown low
positive rates for HPV-16 E6-/E7-specific memory cytotoxic
T-cells, ranging from 12% to 20%, among CIN and ICC pa-
tients (3, 12, 23, 26). However, at least one recent study using
a highly sensitive method has detected an HPV-16 E6-/E7-
specific memory cytotoxic-T-cell response in all cervical cancer
patients (31). Another study of patients with low-grade squa-
mous intraepithelial lesions showed that while a T-cell re-
sponse was detected only in half of the patients, the presence
of an E2-specific T-cell response correlated with the absence of
progression (36). The possibility of augmenting a preexisting,
though generally low-level memory cytotoxic-T-cell response
leading to the clearance of an established lesion is supported
by the results of a recent clinical trial on treating vulvar intra-
epithelial neoplasia using a synthetic long-peptide vaccine (18).
To date, data on the T-cell response to non-16/-18 high-risk
HPV types are not available. We took advantage of having a
higher prevalence of HPV-58 in our population to examine the
T-cell response to HPV-58 infection. The majority of studies of
Western women have focused on a T-cell response restricted
by HLA-A*0201 (3, 12). Our study population comprised a
large proportion of subjects with HLA-A11 restriction and,
therefore, provided some unprecedented data in this area.
In this study, we used an IFN- ELISPOT assay to measure
the T-cell response because it has the advantage of being less
cumbersome than the formal cellular cytotoxicity assay. Al-
though the IFN- ELISPOT results correlate with cytotoxicity,
one should note that the assay used in this study does not
measure the antitumor cytotoxic response directly. Overall, we
found that T-cell responses against L1 peptides were mainly
observed from subjects who had recently cleared an HPV-58
infection, while T-cell responses specific for E6 and E7 pep-
tides were largely confined to subjects who had developed CIN
or ICC. This observation is in line with the expression profile
of HPV proteins among different grades of cervical lesion. In
cleared infections with normal or low-grade cervical cytological
or histological abnormalities, the viral capsid protein L1 is
abundantly expressed in the upper, differentiated layer of ep-
ithelial cells (11). These proteins may be exposed to antigen-
presenting cells with subsequent stimulation of the immune
system. The L1-specific T-cell response seems to be short-lived
and to disappear once the antigen is no longer expressed, as
such response was not observed in patients with CIN3 or
above. The current study has identified four potential A11-
restricted L1 epitopes, with three of them (amino acid posi-
tions 101 to 109, 327 to 335, 469 to 477) showing significantly
higher positive rates for subjects who had cleared the infection.
It is worth noting that the epitope (L1 296-304) containing a
common B-cell epitope (DLYIK) that is present on the surface
of virus-like particles also elicited a T-cell response from two
subjects with cleared infection and four subjects with CIN2.
Although we did not observe a significant difference in re-
sponse rate between subjects with single and coinfections, the
possibility that some of the positive response might due to
cross-reactivity with other HPV types could not be excluded. In
fact, four of the five L1 epitopes showing a positive response
share a high degree of similarity with HPV-16 or HPV-18. It
would be interesting to investigate whether the B-cell response
also targets epitopes that share a high degree of similarity
among different types of HPV and, thus, elicit cross-type im-
munity following natural infection or vaccination.
Our results showed that T-cell responses to E6 and E7
peptides were only detected infrequently in patients with CIN2
or higher severity disease and, in general, the positive rate
among each disease group was less than 20%. This observation
may suggest that for subjects who have progressed to CIN2 or
higher severity disease, the virus has found a way to escape
immune surveillance. Nevertheless, our assay may not be sen-
sitive enough to detect very low levels of T-cell response.
Higher response rates have been reported when whole pro-
teins, as opposed to single-epitope-restricted peptides, were
used in in vitro restimulation (3). Furthermore, an HPV-16
E6-specific memory T-helper response was demonstrated in a
substantial proportion of healthy individuals (34), and a lack of
cytotoxic response to HPV-16 E6 was also linked to the per-
sistence of infection (22). By examining the T-cell response
directly ex vivo, the CD4 but not the CD8 response was
found to be lower among those with progressive disease (30).
These findings, together with the results of a recent clinical
trial, indicate that there is still a potential to develop thera-
peutic vaccines to clear established lesions (18).
One limitation of this study is the relatively small number of
subjects examined in each disease category. While we at-
tempted to perform statistical analysis on the response rates
for each peptide, the type 1 and type 2 statistical errors re-
mained large because of the small sample size. Hence, the
statistical significance observed in this study should be taken as
a reference for further, more extensive study rather than as
final.
We found an E7 epitope (amino acid position 74 to 82) that
was broadly reactive across all disease groups. This epitope
may be a more immunogenic one, for which even a relatively
small amount of E7 protein produced during transient infec-
tion is sufficient to elicit a T-cell response. Since the response
rate to this epitope was similar across all disease groups, it does
not seem to play a protective role. We have also identified two
E6 peptides (amino acid positions 64 to 72 and 94 to 102),
three A11-restricted E7 peptides (amino acid positions 74 to
82, 78 to 86, and 88 to 96), and one A2-restricted E6 peptide
(99 to 107) for which a natural T-cell response could be de-
veloped. Nevertheless, it is not known whether these HPV
peptides are naturally processed and presented in cervical ep-
ithelial cells. Furthermore, our results only suggest that these
epitopes are immunogenic. Further study is required to verify
whether these epitopes can elicit a protective immune re-
sponse.
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